Minority report by Senators Milne and Allison
THE INQUIRY
1.1
In January 2006 the Senate Community Affairs Committee (the Committee)
received correspondence from Dr Robert Ware raising a number of issues relating
to the assessment of PET by the Medical Services Advisory Committee (MSAC) in
2000 and requesting an inquiry into 'the conduct of the Government's PET
scanning policy since 1999'.[1]
Issues associated with PET and the MSAC Review in 2000 had been the subject of
questions by Senators during estimates hearings over a period of time. In his
correspondence, Dr Ware contended that the Department of Health and Ageing
(the Department) had 'submitted, and then failed to retract, false information'
in response to a question on notice during estimates proceedings.
1.2
The Committee agreed that, with an allegation of misleading evidence, it
would hold a hearing to enable the issues in Dr Ware's correspondence to be
raised and responded to by the Department. The Committee considered the matter
at a public hearing in Canberra on 28 April 2006. This hearing generated a
substantial volume of information and documents being provided to the Committee
that required detailed assessment. The Committee considered that further
hearings on this matter would be needed and these were held on 30 March 2007 and 14 June 2007. Members of the Committee also inspected the PET
facilities at the Peter MacCallum Cancer Centre in East Melbourne on 22 August 2007.
1.3
The Committee's concern in this matter was whether false information had
been given during the estimates proceedings and whether the processes used to
make the decisions on the use and the funding of PET were appropriate, and
reflected the contributions of people on the various expert committees. The Committee
was not inquiring into the clinical value of PET or whether PET should have
been viewed as clinically effective when it was first assessed by MSAC in
1999-2000.
1.4
A list of the documents authorised for publication by the
Committee is at Appendix 1. A list of the witnesses who gave evidence at the
hearings is available at Appendix 2. The Hansard transcript of evidence may be
accessed through the Hansard website at https://www.aph.gov.au/hansard/.
BACKGROUND
Positron Emission Tomography (PET)
1.5
Positron Emission Tomography (PET) is a diagnostic imaging technology
that uses short-lived radioisotopes to enable the non-invasive imaging of
metabolic functions within the body. To conduct the scan a short-lived
radioactive tracer isotope, which decays by emitting a positron and which has
been chemically incorporated into a metabolically active molecule, is injected
into a patient. The molecule most commonly used for this purpose is
fluorodeoxyglucose (FDG). While computed tomography (CT) and magnetic resonance
imaging (MRI) primarily provide information about anatomical structure, PET can
image and quantify biochemical and/or physiological function. PET can be used as
a means of diagnosis for a range of clinical conditions, including many cancers.
The widespread use of PET is limited by the costs of cyclotrons required to
produce the materials used for PET scanning as well as the need for trained
staff and specialised equipment.
The Medical Services Advisory
Committee (MSAC)
1.6
The Medical Services Advisory Committee (formerly the
Medicare Services Advisory Committee), or MSAC is the main body responsible for
assessing medical technology in Australia. Most MSAC members are appointed by
the Minister, and are selected on the basis of their expertise and standing in
medicine or health economics.
1.7
The then Minister for Health and Family Services[2],
Dr Michael Wooldridge, established MSAC in April 1998, replacing the
Australian Health Technology Advisory Committee (AHTAC). In launching MSAC, the
Minister said the 'introduction of evidence based medicine and this committee
means that the gap between research knowledge and clinical practice will narrow'.
He noted that the 'MSAC committee is charged with overseeing a process where
evidence and science are the only points of reference'.[3]
1.8
At the time PET was assessed, the MSAC terms of reference were
to:
- Advise the Minister for Health and Aged Care on the strength
of evidence pertaining to new or emerging medical technologies and procedures
in relation to their safety, clinical and cost effectiveness and under what
circumstance public funding should be supported.
- Advise the Minister on which new medical technologies and
procedures should be funded on an interim basis to allow data to be assembled
to determine their safety, effectiveness and cost effectiveness.
- Advise the Minister on references related either to the new
and/or existing medical technologies and procedures.
- Undertake health technology assessment (HTA) work referred by
the Australian Health Ministers’ Advisory Council (AHMAC).[4]
1.9
The MSAC process for assessing medical technologies is in
several stages. A description of the process from the first MSAC annual report during
the time when PET was assessed provides a useful summary and is extracted below.
Stage 1 – Eligibility
The first stage of the MSAC assessment cycle involves
consideration within the Department of Health and Aged Care of an application’s
eligibility for assessment by MSAC.
Stage 2 – Assessment
If an application is considered eligible for review it moves
onto the second stage, assessment. MSAC utilises independent contractors to conduct
the majority of the evidence based assessment. This involves the development of
an evaluation protocol and assessing the available evidence on the safety,
clinical effectiveness and cost effectiveness of the technology or procedure.
MSAC appoints a specialist Supporting Committee, chaired by a
member of MSAC, to assist in the assessment of each application. This provides
expert input into the assessment process as well as ensuring that the
contractors assessment is clinically relevant.
Stage 3 – Formulation of advice to the Minister
In formulating recommendations to the Minister, MSAC considers a
range of information. This includes the assessment report and any feedback on
the report received from the MSAC applicant or the Department.
MSAC recommendations generally fall into one of three
categories:
- The evidence is strong and supports public funding;
- The evidence does not support public funding; or
- The
evidence is inconclusive but suggests that the procedure could be safer, more effective,
and more cost-effective than comparable procedures that attract public funding.
In these circumstances, MSAC may recommend interim funding to enable data
collection and further evaluation of the procedure.
Stage 4 – Decision
The Department makes a submission to the Minister for Health and
Aged Care that combines MSAC’s final assessment report and recommendations with
policy advice from the Department. The Minister considers this information and
makes a decision to endorse or reject the MSAC recommendations. To date the Minister
has endorsed all MSAC recommendations.
Stage 5 – Implementation
If the Minister endorses a recommendation for Commonwealth
funding of a new medical service, the appropriate consultative committee draws
on MSAC’s findings to determine funding levels. The appropriate committee is
determined primarily by the nature of the service, however relevant committees
include the Medicare Benefits Consultative Committee, the Consultative
Committee on Diagnostic Imaging and the Pathology Services Table Committee.[5]
The review of PET
1.10
In 1999, MSAC received applications from Professor Ken Miles
at Wesley Hospital and Dr John Morris at Peter MacCallum Cancer Centre seeking an
extension of Medicare funding for the use of PET. The Chair of MSAC, Professor
David Weedon, wrote to the then Minister for Health and Aged Care, Dr Michael
Wooldridge, to advise him that MSAC had received an application to assess PET. Professor
Weedon stated that MSAC agreed 'the role of PET in the Australian health system
needs to be clarified, and appropriate funding models considered, so that the
application can be assessed in the broader context' and sought advice on how
the Minister wished to proceed.[6]
1.11
In response to this request for advice, the Minister
instructed the Department of Health and Aged Care (now the Department of Health
and Ageing) to set up a review of PET 'that would incorporate an assessment by
MSAC, but also consider a broader range of issues including technical
specifications, funding models, an appropriate distribution of services, and
ongoing evaluation'.[7]
The Diagnostic and Technology Branch of the Department conducted the review
with the guidance of a Steering Committee comprising representatives of the
medical profession, State and Territory governments and consumers. The Steering
Committee was responsible for consideration of the broader policy issues
associated with PET, and for the preparation of the review report and
recommendations for presentation to the minister.[8]
1.12
Professor Weedon later explained the purpose of the
Steering Committee:
Because positron emission tomography (PET) has the potential to
become a major expense for the Federal Government, MSAC recommended that the
Minister establish a special committee (independent of the MSAC process, but
with an MSAC member for coordination) to report on the need for this technology
in Australia and its funding. The Minister has accepted this recommendation.[9]
1.13
The Department established an advisory committee (the
Steering Committee) with the following members:
Professor Brendon Kearney, Chair
Dr Geoff Bower, Australian and New
Zealand Association of Physicians in Nuclear Medicine
Dr George Klempfner, Royal
Australian and New Zealand College of Radiologists
Dr Gabrielle Cehic, Royal Australasian
College of Physicians
Mr Clive Deverall, Consumers' Health
Forum
Dr Richard King, Ex officio
member—Medicare Services Advisory Committee
Associate Professor Stephen Boyages,
States and Territories representative
Professor Michael Quinlan, States
and Territories representative
Mr Alan Keith, Department of Health
and Aged Care
Dr John Primrose, Department of Health
and Aged Care.[10]
1.14
Following its process, MSAC convened a Supporting Committee
to assess PET with the following members:
Dr Richard King, Chair
Professor Brendon Kearney, Ex
officio member—Chair of Review Steering Committee
Dr Rodney Hicks, Australian and New
Zealand Association of Physicians in Nuclear Medicine
Dr Ken Miles, Royal Australian and New
Zealand College of Radiologists
Associate Professor Andrew Scott, Australian
and New Zealand Association of Physicians in Nuclear Medicine
Associate Professor Michael Fulham, Australian
Association of Neurologists
Professor Robert Thomas, Royal Australasian
College of Surgeons
Dr Michael Millward, Royal Australasian
College of Physicians
Dr Michael Kitchener, Medicare
Services Advisory Committee
Associate Professor Richmond Jeremy,
Cardiac Society of Australia and New Zealand
Dr John Primrose, Department of
Health and Aged Care.[11]
1.15
The terms of reference for the review, as presented to the
first meeting of the Steering Committee in October 1999 were:
- To assess,
in conjunction with MSAC and the profession, and with reference to available
sources of evidence, the cost effectiveness, clinical effectiveness and safety
of PET, especially in relation to comparable technologies such as magnetic
resonance imaging.
- To report on
and assess, in conjunction with MSAC, the state of PET technology, recommending
preferred technical specifications and approaches where appropriate.
- To clarify
the role of PET in Australian clinical practice, including:
- determining
which indications/applications should be eligible for funding; and
- where
funding is appropriate, determining suitable funding models.
- To develop,
in consultation with stakeholders including the profession and State and
Territory governments, a national strategy aimed at ensuring appropriate
distribution of and access to PET services.
- To develop,
in consultation with stakeholders including the profession and State and
Territory governments, a data collection and analysis plan to enable the
ongoing evaluation of PET.[12]
1.16
At its first meeting the Steering Committee considered the
roles and responsibilities of the various bodies involved in the review:
The MSAC Supporting Committee will oversight a technical
evaluation of PET, including an assessment of clinical need, safety,
effectiveness and cost effectiveness. The NHMRC [National Health and Medical
Research Council] Clinical Trials Centre, under an existing contract with the
Department, will conduct a systematic review of PET.
The Steering Committee will focus on broad policy questions
related to national health planning. The MSAC Supporting Committee's evaluation
will inform the Steering Committee's consideration of and recommendation on
safety standards, practice guidelines, accreditation and training, distribution
of and access to PET services and ongoing evaluation.[13]
1.17
The MSAC Supporting Committee also discussed the terms of
reference and the roles and responsibilities of the two committees. The minutes
for 29 November 1999 noted:
The committee agreed that in cooperation with the NHMRC CTC they
were jointly responsible with the Steering Committee for ToR one, assessing the
clinical need, safety, clinical effectiveness and cost effectiveness of PET in
relation to diagnostic modalities.
.....
It had been suggested that the Steering Committee would address ToR
three, to clarify the role of PET in Australian clinical practice. However
given time constraints and clinical experience, the committee members felt that
the Supporting Committee was best placed to determine which
indications/applications should be considered for funding (ToR 3, Part A).[14]
1.18
Dr Richard King, Chair of the Supporting Committee, took this
proposal to a meeting with the MSAC Executive on 30 November 1999.
There was in-principle endorsement of the proposed changes.
However it was agreed that, rather than formally alter the terms of reference
at this stage of the Review, the Chairs of the Steering and Supporting
Committees should liaise closely to ensure that all terms of reference are
addressed without duplication of effort between the two committees.[15]
1.19
The MSAC Supporting Committee reviewed the use of PET in
the following indications:
- pre-operative staging of non-small cell lung cancer (NSCLC);
- potentially resectable melanoma;
- residual/ recurrent mass in patients treated for malignant
glioma;
- suspected recurrence of colorectal cancer (CRC);
- medically refractory epilepsy; and
- assessment of myocardial viability in patients being considered
for coronary revascularisation.
1.20
Between November 1999 and March 2000, the Supporting
Committee met a number of times to scope the assessment and consider material
prepared by the National Health and Medical Research Council Clinical Trials
Centre. There was disagreement within the Supporting Committee regarding aspects
of the contractor's assessment of PET. The minutes of meeting on 28 February 2000 note that the Chair advised members 'there was a place for members to put
in a minority opinion'.[16]
In response to Dr King's offer, Dr Hicks
submitted a document headed, "Report of the MSAC Supporting Committee to
the National PET Review". Dr Hick's document was edited by Dr King and Dr Kitchener,
recommendations were added, and the new document was presented for discussion
to the final Supporting Committee meeting, in addition to the draft report
prepared by the contractors.
1.21
In a teleconference on 23 March 2000 the Supporting Committee agreed on the recommendations of a draft report.[17]
No minority opinions were noted in the Supporting Committee draft report. During
the teleconference, the Department 'clarified for members that the final
evaluation report will be presented as MSAC's view not that of the Supporting
Committee'.[18]
The text of the recommendations from the MSAC Supporting Committee report is
extracted below:
Recommendations
Based on the results of the NHMRC Clinical Trials Centre's
evaluation and the clinical experience of Committee members, the MSAC
Supporting Committee concludes that there is insufficient evidence of PET's
clinical or cost effectiveness with respect to the six indications reviewed to
warrant unrestricted MBS funding.
While the Committee agree that unrestricted funding is
unwarranted at this time, the evidence suggests that PET is safe, clinically
effective and potentially cost effective in the indications reviewed. On this
basis the MSAC Supporting Committee recommends that PET be funded for the
following clinical scenarios.
....
Suggested Funding Mechanism
It is recommended that interim funding be made available
for the above indications, subject to the provision of data.[19]
1.22
The Department has indicated that the 'path taken by
material drafted by the contracted evaluators and considered by the supporting
committee was first to the MSAC executive, then to the steering committee where
it was modified and then to MSAC'.[20]
The Department’s version of events
conflicts with the documentary evidence provided, as there is no record that
the Steering Committee altered the material drafted by the contractors. There
is no evidence in the documents provided that the addition of recommendations
and findings, attributed to the Supporting Committee, were discussed or
authorized by the members of the Supporting Committee or the Steering Committee.
1.23
On 6 April 2000 the Steering Committee was advised that the
MSAC executive had given its approval to consider the Supporting Committee's report.
The minutes of that meeting note 'Dr King explained the findings and
recommendations arising out of the MSAC Supporting Committee's technical
evaluation'. The Steering Committee also referred to changes to the Supporting
Committee report. The relevant parts of the minutes are extracted below.
The [Steering] Committee agreed with the general conclusions and
recommendations of the MSAC Supporting Committee. However, members suggested
some minor changes to the wording of certain recommendations. These changes
have been incorporated in the revised draft approved indications and revised
draft Steering Committee finding and recommendations at Attachment A and B
respectively.
Action(s) arising:
The Department will amend the wording of some of the Supporting
Committee's recommendations for inclusion in the MSAC Supporting Committee and
the Ministerial report.[21]
1.24 The Steering Committee
were never asked to approve alterations to the draft Supporting Committee
report, but instead were presented with a document headed “Revised Approved
Indications” that was approved with minor further modifications.
1.24
The recommendations contained in the original draft
Supporting Committee report were amended by unknown authors, at an unknown
time, but were never authorized by either the Supporting Committee members or
by the Steering Committee members. The altered findings presented to MSAC,
incorrectly purported to be findings of its Supporting Committee are extracted
below.
General Findings
The MSAC Supporting Committee concludes that:
- there is
insufficient evidence at this time from which to draw definitive conclusions
about the clinical effectiveness and cost effectiveness of PET;
- in most
indications PET is used in addition to other diagnostic modalities. This was
the case in the diagnostic algorithm used for the current assessment;
- in terms of
adverse patient reaction to administration of FDG, FDG PET is safe; and
- further
evaluation of the technology is necessary.
Approved Recommendations
The PET Review MSAC Supporting Committee concludes that there is
insufficient evidence on PET's clinical or cost effectiveness with respect to
the six indications reviewed to warrant unrestricted MBS funding.
While the Committee agree that unrestricted funding is
unwarranted at this time, the evidence suggests that PET is safe, potentially
clinically effective and potentially cost effective in the indications
reviewed. On this basis the MSAC Supporting Committee recommends that PET be
funded for the following clinical scenarios.
....
Funding Recommendation
It is recommended that interim funding be made available
for the above indications, subject to the provision of data.
1.25
MSAC considered the assessment of PET on 24 May 2000 and Dr King spoke to the altered Supporting Committee draft report as if it were the
Committee's original report. In the minutes of the meeting there was no
indication that MSAC members were aware that the Supporting Committee draft
report had been altered without the consent of the Supporting committee members.
Dr King confirmed in evidence that the MSAC members were not informed that
the findings and recommendations in the documents they were considering had not
been authorised by the Supporting committee members. Dr King did not consider
that the change was material advising:
I did not think it was a substantive
change and I think it made it a more logical continuation of the first
recommendation by the subcommittee, which was that there was insufficient
evidence on PET’s clinical effectiveness. If there was insufficient evidence of
PET’s clinical effectiveness, how can it be said in the next sentence that it
was clinically effective?[22]
1.26
The minutes of the MSAC meeting also indicated that:
Dr Jackson has been asked to critique the draft report, and will
also speak to it.
In October 1999, the Minister for Health and Aged Care directed
the Department to conduct a review of PET from a national perspective. Professor
Kearney chairs the steering committee which is undertaking the review. MSAC
was asked to contribute to the review's findings by undertaking as assessment
of the technology under its criteria of safety, effectiveness and
cost-effectiveness.
Consideration of the two applications for PET funding has been
deferred pending the completion of the Commonwealth PET review. While the
applicants have not, therefore, been asked for comments on the report, both
were represented on the supporting committee.[23]
1.27
Dr Terri Jackson's commentary tabled at the MSAC meeting on
24 May 2000 discussed the roles and responsibilities of the various bodies
involved in the PET review. Her commentary also discusses the need for a
'seamless' MSAC report to address the 'practical problem' which could result
from differing findings and recommendations in the multiple reports.
MSAC's role in endorsing this Report is different from our
standard role in recommending services for CMBS [Commonwealth Medicare Benefits
Schedule] listing. Here we have been asked by the Minister to provide
scientific advice to a Ministerial Review Committee chaired by Dr Brendon Kearney.
...
It may be that the Minister intended the Supporting Committee to
report directly to the Commonwealth review, in which case MSAC has no formal
role other than lending administrative support and we are not obliged to
consider it further.
However, previous MSAC reports have been MSAC documents
(with due acknowledgement of the work of the supporting committee and the
agency preparing background information). To achieve this in future,
I would suggest that we adopt as policy the preparation of
'seamless' drafts from Supporting Committees (in the 'voice' of MSAC) for MSAC
endorsement.
Where the Supporting Committee is unable to reach consensus,
alternative text be provided expressing the alternatives supported by Committee
members for MSAC final determination.
Whatever our decision about the substance of the PET Report,
I suggest that it be edited into a 'seamless' format for endorsement by the
MSAC Executive prior to public release or publication.[24]
1.28
The draft report notes that in general discussion during
the MSAC meeting:
Dr King noted that funding issues are the prerogative of the
Commonwealth Review Steering Committee but that the objective was to retain
funding at the current level. He also advised that a key objective of the
three-year data collection would be to obtain data on PET's impact on clinical
management.[25]
1.29
The draft report of the MSAC meeting also notes that:
On the strength of the evidence, members endorsed the thrust of
the draft recommendations – that interim public funding for PET should be
supported under the conditions outlined by Dr King ... It was determined that the
exact wording of the recommendations will be determined within the next
fortnight, then sent to all members for comment and endorsement, and finalised
by the Executive and Dr King.[26]
1.30
During a teleconference on 9 June 2000, MSAC noted 'that a majority of MSAC members – 9 members out of 14, with Dr Kitchener abstaining –
endorsed the recommendations of the MSAC supporting committee for PET'.
It was agreed that the MSAC report on the clinical applications
of PET should feed into the Commonwealth Review Steering Committee report, ie,
there should not be two separate reports going forward to the Minister. MSAC
might attract criticism if it were deemed to have gone beyond its ambit. Hence,
MSAC's recommendations to the Review will end with the discussion of 'approved
indications', and not extend to the discussion from 'Suggested funding
mechanisms' onwards.[27]
1.31
The Department noted that the published MSAC assessment
report 'was a consolidation of supporting committee report, contractor's report
and the finding and recommendations of steering committee'.[28]
1.32
The final recommendations of the published MSAC assessment
report are extracted below.
Recommendations
MSAC concludes that:
- there is insufficient evidence at this time from which to draw
definitive conclusions about the clinical effectiveness and cost-effectiveness
of FDG PET;
- in most indications, FDG PET is used in addition to other
diagnostic modalities (and this was the case in the diagnostic algorithm used
for the current assessment);
- in terms of adverse patient reaction to administration of FDG,
FDG PET is safe; and
- further evaluation of the technology is necessary.
Approved indications
MSAC concludes that, with respect to the indications reviewed,
there is insufficient evidence on FDG PET's clinical or cost-effectiveness to
warrant unrestricted Medicare Benefits Schedule (MBS) funding.
While unrestricted funding is not warranted at this time, the
evidence suggests that FDG PET is safe, potentially clinically effective and
potentially cost-effective in the indications reviewed. On this basis MSAC
recommends that FDG PET be funded on an interim basis for the following clinical
scenarios.
....
Suggested funding mechanism
MSAC recommends that interim funding be made available for the
above indications, subject to the provision of data.
MSAC recommends that individual FDG PET facilities' access to
interim funding be dependent on those facilities' collection of data relating
to FDG PET's clinical and/or cost-effectiveness and the provision of that data
to a central coordinating body. Data collection should occur within
MSAC-approved prospectively designed studies that are capable of providing
evidence to enable more long-term decisions to be made regarding the role of
FDG PET in Australian clinical practice.[29]
1.33
The MSAC Assessment Report on PET was attached to
the Report of the Review of Positron Emission Tomography produced
by the Steering Committee. The Steering Committee noted in the Report that an
'integral part of the review was a technical and scientific evaluation of PET,
conducted by a supporting committee of the Medicare Services Advisory Committee
(MSAC)'.[30]
1.34
The Report of the Review of Positron Emission Tomography
also notes that:
MSAC concluded that there is insufficient evidence on PET's
clinical or cost-effectiveness with respect to the six indications reviewed to
warrant unrestricted MBS funding. However, the evidence suggests that PET is
safe, clinically effective and potentially cost-effective in the indications
reviewed.
Many potential questions concerning the use of PET have not been
addressed in the current assessment report. It should not be assumed that there
is no role for PET in the areas not addressed.[31]
1.35
However in its own findings and recommendations the
Steering Committee found:
5. The review steering committee accepts MSAC’s conclusion that
there is insufficient evidence on FDG PET’s clinical or cost-effectiveness with
respect to the indications reviewed to warrant unrestricted funding through the
Medicare Benefits Scheme (MBS).
6. While the steering committee agrees that unrestricted funding
is unwarranted at this time, the evidence suggests that FDG PET is safe,
potentially clinically effective and potentially cost-effective in the
indications reviewed. On this basis the steering committee recommends that FDG
PET be funded on an interim basis for the following clinical conditions...[32]
1.36
Notably, the word 'potentially' does not precede
'clinically effective' in the first description of the MSAC Assessment Report
on PET. The recommendations of the Report of the Review of Positron Emission
Tomography were endorsed by the Minister for Health and Aged
Care in August 2000.
1.37
MSAC has produced a number of further assessment reports
regarding the use of PET. Following an assessment of PET for non-small-cell
lung cancer and solitary pulmonary nodules, MSAC recommended that public
funding should be supported. Similarly MSAC recommended public funding should
be supported for the use of PET prior to surgery in patients with refractory
epilepsy. These recommendations were accepted by the Minister for Health and
Ageing on 2 March 2005.[33]
ISSUES
1.38
Dr Ware, in his initial correspondence to the Committee, called
for an inquiry into the Commonwealth's policy on PET and raised a number of concerns
regarding the review and treatment of PET by MSAC. These included that, at the
outset, the Review of PET had the objective of retaining funding for PET at the
current level and that the Commonwealth had, over a period of years, promoted
unsound healthcare information regarding the clinical value of PET.[34]
Dr Ware's main contention was that the Commonwealth had compromised the
independence of the MSAC by: preventing the processing of properly submitted
applications; direct ministerial intervention in the process; and not following
standard operating procedures for the MSAC.[35]
In particular he argued that the Supporting Committee's report had been altered
without the agreement of its members.[36]
1.39
The Committee also received evidence from Professor Rodney Hicks,
who was a member of the MSAC Supporting Committee which assessed PET. Professor
Hicks considered the changes made by the Steering Committee to the Supporting
Committee's report changed the substance of the recommendations and did not
reflect the evidence. In particular he noted the Supporting Committee had not
been offered the opportunity to dissent or present a minority opinion regarding
the changed Supporting Committee report presented to MSAC. He also raised his
concerns that inaccurate information as to the clinical value of PET had been
published under the names of the experts on the Supporting Committee.
1.40
Professor Hicks stated:
The primary finding that there was 'insufficient evidence at the
time to make definitive conclusions about the clinical or cost effectiveness of
PET', made in response to the first term of reference of the PET Review, cast
unequivocal and pejorative doubt on whether this technology 'works'... This
finding was never presented to us and is fundamentally in conflict with both
our actual recommendation and the body of the report... By inserting this primary
recommendation at the very start of the report, readers are left with the impression
that the experts involved in performing a review of the scientific evidence,
including experts like myself had found the evidence fundamentally wanting.
This had the effect of influencing local and international health-policy
makers, the medical profession and patients seeking 'the best possible
evidence' regarding this technology.[37]
Changes to Supporting Committee
document
1.41
A large number of amendments were made between the versions
of the report. There appear to be two main disputed differences between the recommendations
of the Supporting Committee draft report attached to the minutes of the meeting
of 23 March 2000 and the altered Supporting Committee report considered by
MSAC on 24 June 2000. The first is the inclusion of the 'General finding'
that 'there is insufficient evidence at this time from which to draw definitive
conclusions about the clinical effectiveness and cost-effectiveness of PET'
(separate from the results of the six specific indications reviewed). The
second is the addition of the word 'potentially' before 'clinically effective'
in the recommendations.
Table. 1 – Comparison of original
Supporting Committee report recommendations and altered recommendations
Recommendations of draft report approved by the
Supporting Committee
|
Recommendations of Altered Supporting Committee
report as considered by MSAC
|
Recommendations
Based on the results of the
NHMRC Clinical Trials Centre's evaluation and the clinical experience of
Committee members, the MSAC Supporting Committee concludes that there is
insufficient evidence of PET's clinical or cost effectiveness with respect to
the six indications reviewed to warrant unrestricted MBS funding.
While the Committee agree
that unrestricted funding is unwarranted at this time, the evidence suggests that
PET is safe, clinically effective and potentially cost effective in the
indications reviewed. On this basis the MSAC Supporting Committee recommends
that PET be funded for the following clinical scenarios.
....
Suggested Funding
Mechanism
It
is recommended that interim funding be made available for the above
indications, subject to the provision of data
|
General Findings
The MSAC Supporting Committee
concludes that:
- there is insufficient evidence at this time from
which to draw definitive conclusions about the clinical effectiveness and
cost effectiveness of PET;
- in most indications PET is used in additional to
other diagnostic modalities. This was the case in the diagnostic algorithm
used for the current assessment;
- in terms of adverse patient reaction to
administration of FDG, FDG PET is safe; and
- further evaluation of the
technology is necessary.
Approved Recommendations
The PET Review MSAC
Supporting Committee concludes that there is insufficient evidence on PET's
clinical or cost effectiveness with respect to the six indications reviewed
to warrant unrestricted MBS funding.
While the Committee agree that unrestricted funding
is unwarranted at this time, the evidence suggests that PET is safe,
potentially clinically effective and potentially cost effective in the
indications reviewed. On this basis the MSAC Supporting Committee recommends
that PET be funded for the following clinical scenarios.
....
Funding Recommendation
It
is recommended that interim funding be made available for the above
indications, subject to the provision of data.
|
1.42
The Committee heard evidence from Associate Professor Richard
King who acknowledged that, as Chair of the Supporting Committee, he took
responsibility for the changes made by the Steering Committee to the Supporting
Committee's report. He argued that amendments were made to parts of the
recommendations which he believed did not read together logically. It should be
noted that Dr King's evidence related to agreed alterations to the Steering
committee's draft report and that he did not admit that he was involved in the insertion
of the primary finding to the Supporting Committee's original report. His
evidence is corroborated by the records of the Steering committee's meetings.
1.43
Associate Professor King stated:
I did not make that change. I agreed to the change being made by
the superior committee. It was not made by anyone in the health department; it
was not made overnight; it was not a fly-by-night decision. It was made purely
and simply so that the document read logically.[38]
...
There were editorial changes made to that primary finding which
did not change the meaning of the primary finding at all and which did not
change the outcome of the review at all. If you can point out to me how they
have changed the meaning, I would be more than happy to accept that we have
made a mistake. But saying that there is insufficient evidence at this time to
draw definite conclusions about the clinical effectiveness and cost
effectiveness of PET reads to me as the same but somewhat better worded than
saying that the MSAC Supporting Committee concludes that there is insufficient
evidence on PET's clinical or cost effectiveness with respect to the six
indications reviewed—which were all the indications reviewed—to warrant
unrestricted MBS funding.[39]
...
If there had been a change of intent, I would not have supported
it, but I cannot honestly see how inserting the word 'potentially' into the
second recommendation does not act in synchrony with the first recommendation,
which is that there is insufficient evidence on PET's clinical effectiveness.
That certainly makes it potentially clinically effective, but you cannot then
turn around in the next paragraph and say it is clinically effective if the
evidence says that there is not clinical effectiveness. If you were to read the
report and we had left in that it was clinically effective in the second line,
people from all around the country and internationally would say: 'But you
haven't proved your point. You've said in the first line that there is insufficient
evidence and in the second one, you've said it's clinically effective. How can
that be? [40]
1.44
Associate Professor King also stated:
The concern seems to be the editorialising and the probity of
editorialising one senior committee over a junior committee, which happens in
my experience quite frequently... I cannot see in anything that has been said by Dr
Ware that MSAC is in any way at fault in this regard. If you are finding
fault—and I do not believe that there is fault—then the fault is that of the ministerial
review committee wanting to have wording that it could live with and my fault
in not warning the members of the subcommittee.[41]
1.45
The Department indicated that changes were made to the
Supporting Committee's report by the Steering Committee, but the details of
what was agreed cannot be verified on the basis of the documentary evidence
available. The Department considered that the substance of the report (that
there was insufficient clinical evidence on which to make definitive
recommendations) remained consistent.[42]
Views of other MSAC Supporting
Committee members
1.46
Following Professor Hick's evidence in relation to the lack
of options for the Supporting Committee to dissent to the final report, the
Committee agreed to write to other members of the MSAC Supporting Committee to
give them the opportunity to comment on the matters raised. Several of the MSAC
Supporting Committee members indicated that they did not feel that the findings
and positions of the Supporting Committee on PET were accurately reflected in
the final MSAC report. Professor Michael Millward commented:
The recommendations in the document presented to MSAC diverges
from this [the MSAC Supporting Committee report], in particular the insertion
of the word 'potentially' in front of 'clinically effective' in the final
paragraph. I do not believe this can be considered an 'editorial' change.[43]
Professor Kenneth Miles stated:
...the Supporting Committee's view was that there was sufficient
evidence for clinical effectiveness, but insufficient evidence of
cost-effectiveness in the Australian healthcare system.[44]
Professor Andrew Scott commented:
The report that was finally submitted to MSAC (as stated in
Appendix A) does not completely reflect the position of Supporting Committee.
In particular, the use of 'potential clinical effectiveness' is not consistent
with the views of the Supporting Committee.[45]
1.47
However Professor Brendon Kearney[46]
and Dr John Primrose considered the final MSAC report did reflect the
Supporting Committee's report. Dr Primrose commented:
I can see no difference in meaning between the two versions of
the 'Recommendations' contained in Appendix A of Senator Humphries letter. The
second is merely an expanded and clearer version of the first.[47]
1.48
An alternative explanation was offered by Professor Robert Thomas,
who indicated that:
My memory was that the committee could not find hard evidence
that PET improved outcomes in cancer but clinical effectiveness was agreed
because of better cancer diagnosis and staging. The original report rather confusingly
states this varied outcome in the first two paragraphs. I have agreed that
there is a subtle change in the final wording which does not make the clinical
effectiveness element as clear as in the supporting committee report. The
significance of this change is in the eye of the beholder.[48]
1.49
Professor Michael Fulham disputed the Supporting Committee
recommendations even before they were altered by the Steering Committee. He
argued the benchmarks used in the assessment for PET were inappropriate.
...I was convinced of the clinical effectiveness of PET as it
related to the 6 indications that were discussed. The benchmark, however,
that was set for the evidence to support the clinical effectiveness of PET,
i.e. randomised controlled trials (RCTs), by the NH&MRC representative on
the MSAC Supporting Committee was, in my opinion, inappropriate for an imaging
technology. Despite arguments to the contrary during the meetings that were
held, this was the standard that was promoted and upheld by the Chairman of the
Committee. It was also emphasised by the clinicians that this standard had not
been set for MR imaging where unrestricted Medicare funding had been recently
granted and it seemed inconsistent and unreasonable to apply this standard to
PET. It is true that in 1999 / 2000 there was a paucity of RCT data on the effectiveness
of PET (but also for all other imaging modalities) and as such it was the opinion
of the NH&MRC representatives and the Chairman that clinical effectiveness was
not proven – so in this circumstance the first part of the "Recommendations"
in Appendix A is correct "Based on the results of the NHMRC....evaluation"
but the second phrase "and the clinical experience of the committee
members", as it related to me and my experience, however is incorrect.[49]
The independence of MSAC
1.50
A key concern raised by Dr Ware was that the independence
of MSAC's assessment of PET had been compromised by the ministerial review and
Steering Committee. This concern regarding 'political interference' was shared
by Professor Hicks who believed 'there was an agenda to restrict the
availability of PET and not to have an increase in PET funding'.[50]
Professor Hicks stated:
I have no evidence to support this, but my suggestion to the
committee is that there was a political objective in the PET review...
At the first meeting [of MSAC], where those applications were
due to be considered, the minister was minuted as being in attendance but not
minuted as having said anything. As an outcome of that meeting, the chair of
MSAC, David Weedon, wrote to Michael Wooldridge to say that we were aware that
the minister had a view about PET and, because of the implications of the
technology, we suggested that the minister have the department conduct a formal
review into this new technology.
A unique process was set up...which had
never been done before and has not been done since. Under this process, there
was a separate steering committee—MSAC and the supporting committee. It was a
very complex organisational structure with certain people represented on
multiple committees and some on none at all. There was very little interaction
between those committees.
At the very first steering committee meeting Brendon Kearney was
minuted as informing the steering committee that they should prepare themselves
that the evidence for PET might be insufficient to warrant unrestricted
funding. That is a clear statement, at least in my mind, that there was a
political outcome that was desirable here.[51]
1.51
Dr Ware commented:
It is always difficult to know why people do things if you are
not there at the time; and this is clearly speculation on my part. I believe
that what happened was that the government, and the minister particularly, were
under enormous pressure over the MRI scan scam. That was well known; it was on
The 7.30 Report. That was an administrative debacle...Everyone there knew that
the issue of conflict confidentiality was paramount and that the minister was absolutely
ropeable about what happened with MRI.
I believe that the minister had made a decision that he did not
want to fund any more PET scanners...I believe that there was a deliberate effort
to massage the scientific data, or the data that the public were going to use
in their own health care, to fit a political objective. I cannot prove that.[52]
1.52
However Associate Professor King stated:
We did not have communication from the minister at all in
relation to this... nobody was going to the minister, the reason no-one was going
to talk to the minister at that stage about anything to do with diagnostic
imaging was that the MRI scandal was still happily going in the background. However,
at no time did we, at any committee I was on, receive any advice from the
minister or the department as to what our outcomes should be.[53]
1.53
The Department argued that the 'final recommendation about
the safety, effectiveness and cost-effectiveness of the technology or procedure
is vested with MSAC'.[54]
The Department stated that MSAC had before it a variety of information
including the Supporting Committee's report, the contractor's report and the
draft Steering committee's finding and recommendations. It also noted that
'MSAC member Dr Terri Jackson, a health economist with the Monash University
Health Economic Unit, provided the critique of the evidence before MSAC'.[55]
The Department stated:
MSAC is not a cipher. Consistent with its usual way of
operating, and with the support of Dr Jackson's written and verbal critique,
MSAC analysed not just the conclusions of the documents before it, but the
substance of the analysis in the evidence.[56]
1.54
The Department highlighted that the 'Minister responded to
the MSAC chair's request for direction on how to approach an assessment of PET
by establishing the PET Review, which was to incorporate an MSAC assessment'.[57]
It also noted that the conclusion that 'funding should be provided on an
interim basis, and for a defined set of indications, were reached on a number
of occasions and by each of the bodies involved in the PET review'.[58]
The Department went on to state:
The process of conveying advice to MSAC,
based on evidence compiled by the evaluators, and the considered opinions of
members of the supporting committee, had no effect on MSAC's advice to the
government. For example, it has been asserted that the insertion of the word
'potentially' in conclusions of the supporting committee might somehow have had
a determinative effect on MSAC's view. This is not so either in this specific instance
or generally.[59]
1.55
The Department indicated it has undertaken 'thorough and
extensive investigations of the processes and procedural activities which
occurred during the Commonwealth review and the MSAC assessment of PET in
2000'. On the basis of this review the Department had found 'no evidence of
fraud committed in relation to the review, by any officer in the Department or
by any member of the MSAC Committees involved in the PET evaluation'.[60]
Dissenting views in Supporting
Committee
1.56
The Committee was concerned that the members of the
Supporting Committee were not given the opportunity to express dissenting
opinions in relation to their report after it had been altered by the Steering
Committee. The Department highlighted that the 'minutes of the third supporting
committee meeting of 28 February 2000 note that the chair of the committee
advised members there was a place for members to put in a minority opinion'.[61]
However this occurred before the report was altered by the Steering Committee
on 6 April 2000, and it appears that the Supporting Committee members
were given no opportunity to express dissent to those changes.
1.57
The guidelines given to the Supporting Committee at the
time that PET was assessed did not address the situation where members wished
to place dissenting views on the record. The Department has acknowledged there
was a flaw with the process of seeking final approval of the Supporting
Committee's recommendations.[62]
The Department noted it was not until August 2000 that guidelines for members
of MSAC Supporting Committees were changed to include the following:
In reporting to MSAC on its
evaluation of an application, the supporting committee’s report should note
whether or not all supporting committee members were in agreement with the
supporting committee’s report. If not, the name of the supporting committee
member(s), and the nature and extent of the dissenting view, should be included
in the supporting committee’s report. Areas of agreement/disagreement amongst
supporting committee members, and by whom these views are held, should be
stated.[63]
1.58
However, Dr Primrose, the Department’s medical adviser to
MSAC at the time confirmed that he knew that MSAC’s dissent provisions were
operational at the time of the 2000 PET Review.[64]
1.59
Professor Hicks asserted that he had provided a 'document
in response to the Chair's offer' which was sent to the Department secretariat
prior to the final meeting of the Supporting Committee on 23 March 2000.[65]
While the Department confirmed that the document was received, it argued that
it formed part of the Supporting Committee's deliberations and should not be
viewed as minority report as it was discussed and incorporated into the
Supporting Committee's draft report at the March meeting.[66]
1.60
The Department acknowledged that there was a flaw with the
process of seeking final approval of the Supporting Committee's
recommendations.
It does not appear that the Supporting Committee was given the
opportunity to formally sign off on its advice to the MSAC before it was
considered by the MSAC Executive, the Steering Committee and subsequently the
full MSAC. [67]
It also noted that MSAC processes have subsequently been
amended to ensure clarity and consistency of procedure. [68]
1.61
Some of the other members of the Supporting Committee
indicated that they may have, or would have, made dissenting views if they had
been offered the opportunity. Professor Scott commented he had been 'provided
with operating guidelines for the Supporting Committee, which do not contain
information on recording of dissenting views'. He stated:
If I had been aware of the alterations to the report, I would
most likely have requested that the Recommendations be changed back to that
which was agreed by the Supporting Committee. I am unsure of what the process
for that would have been. A dissenting view as a final recourse would have been
a possibility.[69]
1.62
Professor Millward noted 'the changes were made after the
MSAC supporting committee had seen what it thought was the final report.
Therefore there was no opportunity to comment on what was presented to MSAC... I
expect I would have expressed a dissenting view...'.[70]
1.63
Professor Miles commented:
I was not given an adequate opportunity to comment or disagree
with the Supporting Committee's report because the report was amended beyond
mere editorial changes after the final meeting of the Committee without being
referred back to the Committee for approval of these changes or opportunity to
dissent. If I had been made aware of these changes, I would have requested my
dissenting views be recorded.[71]
Withdrawal of the report / publishing
of an errata note
1.64
In their evidence to the Committee, Dr Ware and Professor Hicks
argued for the withdrawal of the MSAC assessment report. One of Dr Ware's desired
outcomes was 'to have the deceptive and dangerous recommendations of the 2000
PET review withdrawn from the public domain'.[72]
Professor Hicks also stated that the 'change in the findings... and the impact
that that has had on patients, have damaged my international reputation'.[73]
1.65
Professor Hicks had previously contacted the Department of
Health and Ageing to request his name be removed from the MSAC assessment
report. The Secretary of the Department, Ms Jane Halton replied:
You request in your letter that your name be removed from the
MSAC PET report, in the absence of amendments reflecting your criticisms. Given
the report has been in general circulation for over three years, and no
reprints are anticipated, it would be impracticable to effect your request at
this time.[74]
1.66
In his evidence to the Committee, Professor Hicks stated:
I would like to have my name removed as one of the people who
have endorsed this report, as I have requested repeatedly of Jane Halton in the
department. I ask senators to request that my name be acknowledged as a
dissenting view on this report... I would like the opportunity to have the
recommendation that our committee of experts actually put to Professor
King—that was heavily edited by him before the formulation of that draft report
that you saw—included as an appendix to this document, as a PDF on the MSAC
website.[75]
1.67
Professor Fulham considered '...there would be little
tangible benefit from having the report withdrawn'. He continued:
As to an errata note being issued I am ambivalent and I am not
sure that it will achieve much; at RPA we will perform over 5,000 patient PET
studies this year and our clinical program is second to none in providing a
high quality clinical service to patients and referring Drs and each day we
show the clinical value of PET in patient management. An errata note will have
no effect on this.[76]
1.68
However other members of the Supporting Committee supported
an errata note being issued. For example Professor Scott stated:
I believe that as a member of a Supporting Committee it is
appropriate that the report to MSAC accurately reflect the views of the
Committee. It would therefore be appropriate to consider allowing an errata to
state that members of the MSAC Supporting Committee did not agree with all (or
part) of the report sent to MSAC.[77]
1.69
Professor Miles submitted that:
I would support an errata note being issued provided that the
note indicated the manner in which the members of the MSAC Supporting Committee
did not agree with the findings of the final MSAC report regarding PET, i.e.
that the Supporting Committee found that PET was clinically effective for the 6
clinical indications reviewed, but that there was insufficient evidence of cost-effectiveness
in the Australian healthcare system. If such a specific errata is not
possible, then I would support withdrawal of the report.[78]
1.70
The Department indicated it had sought legal advice and
consulted with the National Archives of Australia regarding Professor Hicks'
request to have his name removed from both reports. The advice the Department
received was that as Professor Hicks is on the public record as having been a
participant in the Supporting Committee for the Review the removal of Professor
Hicks' name would change the historical record, contrary to s. 24 of the Archives
Act 1983.
1.71
The Department proposed to upload a disclaimer specific to
the MSAC Reference 2 Positron Emission Tomography website
noting Professor Hicks' earlier request that 'The primary conclusion in the
reports arising out of the Medical Services Advisory Committee (MSAC) 2000
review of Positron Emission Tomography (PET) undertaken by MSAC
does not reflect the opinion of Professor Rodney Hicks'. The Department
indicated it would be writing to Professor Hicks to seek his confirmation that
'these proposed arrangements address the substance of his concerns'.[79]
1.72
The Department noted that standard MSAC practice was now
for final reports and decisions to be made available on the MSAC website. The
site includes a 'pop-up' disclaimer for each review stating that 'MSAC
recommendations do not necessarily reflect the views of all individuals who
participated in the MSAC evaluation'. In addition MSAC is currently
reviewing how an individual's dissenting views might be made know in its
publicly available information.[80]
The Department reported that the MSAC Executive had agreed that should this situation
arise again a disclaimer specific to the report will be uploaded to onto the
MSAC website noting that:
The primary conclusion in the XXX report arising out of the
review of XXX undertaken by the medical Services Advisory Committee (MSAC) does
not reflect the opinion of XXX (insert name).[81]
Department of Health and Ageing
1.73
In his initial correspondence with the Committee, Dr Ware
also stated that the Department 'submitted, and then failed to retract, false
information in response to a question on notice' put during Community Affairs
Senate Legislation Committee proceedings.[82]
Additionally Dr Ware stated that Department officers had engaged in dishonesty
in response to questions about the formulation and conduct of the
Commonwealth's policy towards PET.[83]
1.74
During his evidence Dr Ware alleged:
I believe these documents will also provide you with irrefutable
evidence that the Department of Health and Ageing has breached the Australian
Public Service Code of Conduct[84]
by providing false and misleading information to this committee on multiple
occasions. Even though senior department officers were made aware of these
material errors of fact, no action has been taken to correct the public record...[85]
1.75
Dr Ware highlighted the answers the Department had provided
to a Question on Notice from Senator Harradine on 5 November 2003.
(a) Did the Scientific Supporting Committee in its report find
that PET scanning was clinically effective and possibly cost effective?
(b) Why were the expert opinions ignored in the final decision?
(c) Is it correct that a specialist from the Peter MacCallum
Clinic wrote to the Chair of Scientific Supporting Committee and the chair of
the Medical Services Advisory Committee (MSAC) requesting that his name be
removed from any connection with MSAC's downgrading of the Scientific
Supporting Committee's report?
The Department responded:
- No. Supporting Committees of the Medical Services Advisory
Committee (MSAC) do not make findings. Neither do Supporting Committees make
reports, this being the responsibility of MSAC. Some members of the Supporting
Committee did provide separate written advice to MSAC and this advice made
stronger claims about the effectiveness and cost-effectiveness of PET than
those of MSAC's findings.
- Expert opinions were not ignored in the final decision.
However, MSAC's recommendations in relation to PET were primarily based on
analysis of the evidence from the international scientific literature, not
individual clinical opinion.
- A specialist from Peter MacCallum Cancer Institute (also a
member of MSAC PET Supporting Committee) wrote to the Secretary for the
Department of health and Ageing on 5 December 2003, referring to his letter
dated 2 April 2003, which he noted had not been sent at that time due to an
administrative error within his office. In the April letter, he requested that,
in the absence of specific changes to the 2000 report of the Review of positron
emission tomography, and the associated MSAC report, his name be removed from
those documents.
This specialist was one of seven clinicians on the PET
supporting committee, which also included representatives of MSAC and the
Department. As is typical of an MSAC review process, the supporting committee's
members expressed a range of views in the course of the committee's
deliberations. However, no committee member other than the specialist in
question made a formal statement of dissent in relation to the PET review's
findings.[86]
1.76
The Department rejected Dr Ware's allegations concerning
the conduct of Departmental officers during this matter stating that 'all
Departmental officers have acted with integrity and professionalism in dealing
with this controversial and difficult issue'.[87]
The Department stated it had 'made every effort to ensure that the secretariat
support provided to MSAC is professional and that record keeping for the MSAC
Committee is accurate'. However the Department also noted that:
In responding to the queries of Dr Ware, Professor Hicks and
members of this Committee, it has become apparent that the quality of minute
taking at the time was not what it should have been. Further, over the years
there have been instances where the Department has supplied incorrect documents
in response to these queries, in large part due to the confusion in
nomenclature of the various parts of the process for that 1999 assessment.[88]
1.77
The Committee finds that the Department did not act with
integrity and professionalism at all times as their own admissions regarding
answers to questions from Senator Harradine, provision of incorrect documents
and inadequate minute taking indicate. Furthermore the letter to the Committee
from Secretary Halton dated 19 February 2008 provided false information to the
Committee.
The role of MSAC
1.78
During the hearing on 30 March 2007 there was discussion regarding possible reform of MSAC. In May 2004, MSAC undertook a review of
its procedures and methods in order to identify opportunities to improve
approaches to, and management of, the assessment of health technologies. In
November 2004, MSAC agreed to implement a number of actions which were
developed using ideas contained in many of the submissions, and which fitted
within its terms of reference. The review was completed in May 2005.[89]
1.79
However Dr Ware argued for further reforms to MSAC which he
stated 'needs to be under legislative control'. He quoted from the Australian
Medical Association submission to the MSAC review to highlight his concerns:
Until MSAC is established on a similar footing to PBAC
[Pharmaceutical Benefits Advisory Committee], it will not enjoy the confidence
of the medical profession. The establishment of MSAC was an attempt to establish
a more independent body at arm’s-length from the government. MSAC is not
established independently of the department or the government. Its agenda in
relation to existing MBS items is almost exclusively determined by the
department and its secretariat. It is made up of departmental officers with
line responsibility to senior departmental officers. The relationships between
the department and the MSAC secretariat and MSAC itself are unclear.[90]
1.80
In the review report MSAC agreed to a number of reforms to
improve the transparency of MSAC assessment processes. These included
developing 'a presentation and associated material that will provide clear,
consistent direction to Advisory Panels [Supporting Committees] about the roles
and responsibilities of panel members, as well as the contracted evaluators and
the department'.[91]
However the report does not appear to address the relationship between MSAC and
the Department and the issue of the independence of evidence-based advice.
CONCLUSION
1.81
As previously stated the Committee's interest in this
matter related to whether the practices and procedures used in assessing PET
were appropriate and whether false information had been provided during
estimates proceedings.
1.82
In the opinion of the Committee, no evidence was provided
to support or disprove the contention that there was inappropriate intervention
by the Minister into the MSAC assessment of PET. However minutes of the
Executive meeting of MSAC dated 30 March 2000 were provided to the Committee.
The Minutes indicate that the original Supporting Committee report was approved
and that Dr King was congratulated for concluding a difficult task. It was
stated that the original Supporting Committee report would be provided to MSAC
for endorsement but also to the Steering Committee to inform its discussions.
The meeting included MSAC's Chair, Dr Kearney and Messrs King, Primrose and Alan
Keith. There was no mention of inconsistency of findings or problems with the
report. Changes were made to the original Supporting Committee report by the
Steering Committee which conflicted with what had been presented to the
Executive. These clearly were material enough to mislead the medical
professionals on MSAC as to the clinical value of PET.
1.83
The Committee finds that MSAC was unaware that the
recommendations it adopted with respect to the clinical value of PET were not
the true findings of the Supporting Committee.
1.84
The Committee finds that MSAC's decision was therefore made
without knowledge of the true Supporting committee recommendation.
1.85
The Committee does not accept the argument that because
MSAC was not obliged to accept the reports and recommendations of the PET
Supporting Committee, the content of the true Supporting committee report was
immaterial to the outcome of MSAC's decision making process.
1.86
However the issues raised by Dr Ware and Professor Hicks
highlight the importance of ensuring the independence of scientific and
technical evidence based assessments of new medical technologies. Allowing the
Supporting Committee's report to be viewed and altered by the Steering
Committee, and by officers from the Department, invited questions of
impropriety into an assessment process which was held up as being based wholly
on scientific and technical evidence. This situation was compounded by the fact
that members of the Supporting Committee had no notification that changes were
being made or the opportunity to have their dissent to the changes recorded.
1.87
The Committee also notes that in the previously outlined
stages of the assessment process, MSAC in formulating recommendations to the
Minister, considers 'a range of information' including 'the assessment report
and any feedback on the report received from the MSAC applicant...'.[92]
The Committee understands that conflicts of interest regarding developing
medical technologies are common and, in many instances, unavoidable given the
relatively small pool of clinical expertise in Australia. In future, it would
be preferable if applicants to MSAC in relation to a new medical technology
were not invited to participate as part of the Supporting Committee assessing
the technology.
1.88
The Committee has noted the review of MSAC assessment
processes and the reforms to improve the transparency of MSAC decisions. This
review does not appear to have considered the specific issue of the
independence of MSAC advice from the Minister or the Department. Arguments were
put to the Committee that MSAC should, like the Pharmaceutical Benefits
Advisory Committee (PBAC), be constituted as a statutory body, at arm's length
from the Government.
1.89
During the hearing on 30 March 2007 a number of allegations were made regarding Associate Professor King in his role as Chair of
the Supporting Committee. In essence, these suggest that Assoc. Prof. King was responsible
for altering the recommendations of the Supporting Committee regarding PET and/or
fraudulently misrepresenting to MSAC that the report was the unaltered
recommendations of the Supporting Committee (after it had been altered by the
Steering Committee).
1.90
As the Chair of the Supporting Committee, Associate
Professor King has taken responsibility for the changes that were made by the
Steering Committee to the Supporting Committee report recommendations and for
presenting them as if they were the original findings of the report. Whilst
there has been no evidence presented that Associate Professor King (or anyone
else) had any intention to mislead or to deceive MSAC or had any reason for
doing anything inappropriate in the changes that were made to the Supporting
Committee report by the Steering Committee, there has been no explanation as to
who authorised the out of Committee insertion of the Primary Finding into the
Supporting Committee report or why they did so. This critical question remains
unanswered and would have gone to the heart of the matter had the Committee
been able to elicit an answer.
1.91
The Committee finds that the recommendations of the
Supporting Committee report were changed with the knowledge of Associate
Professor King and others.
1.92
The Committee finds that the Supporting Committee report
was changed without the knowledge or consent of the Supporting committee
members.
1.93
The Committee finds that the "Primary Finding" of
MSAC from the 2000 Review of PET conflicts fundamentally with the experts views
about the clinical value of PET.
1.94
The Committee finds that a majority of the clinical experts
on the Supporting Committee decided that PET was clinically effective on the
strength of evidence available at that time. The majority disagree with Associate
Professor King's claim that:
- Changes to the supporting Committee recommendations were
merely editorial or drafting changes.
- And the supporting Committee was not of the view that
"there was insufficient evidence".
1.95
The Committee finds that MSAC was deprived of the knowledge
of the Supporting Committee's true decision about the clinical value of PET and
the range of opinions held by the experts regarding the strength of the
available evidence.
1.96
The Committee finds that it was a fundamental breach of
MSAC's due process to allow the recommendations of the Supporting Committee's
Report to be altered without the knowledge of its members because that action
would deprive MSAC of the opportunity to be properly informed of the opinions
held by Supporting Committee members.
1.97
The MSAC assessment of PET highlights the dangers of
ambiguities arising in the roles and responsibilities of the bodies involved in
the review of new medical technologies. The Committee considers that the roles
and responsibilities of the Supporting and Steering Committees in the review of
PET were not clear. For example the Supporting Committee minutes indicate it
agreed 'it was jointly responsible with the Steering Committee for ToR [term of
reference] one, assessing the clinical need, safety, clinical effectiveness and
cost effectiveness of PET in relation to diagnostic modalities'. The Department
has also noted this was a relatively new process with unique circumstances:
....when this matter went through MSAC it
was very early days. I think it was the second application that MSAC had ever
considered and it was the first one where it had this particular structure of
three committees essentially in the main MSAC, a supporting committee and a
steering committee. The steering committee, as I say, I think was the first
example and it had a particular role which you would not normally find
associated with MSAC. [93]
1.98
The Department was wrong in its evidence and it was
corrected during the hearings. It was the second reference but the 19th
evaluation that MSAC had done. It was evaluated as a "reference"
because the government prevented MSAC from evaluating the original
applications. It should be noted in this context that the MSAC guidelines do
not specify a different set of standards or rigour for applications and
references.
1.99
The majority of the Committee consider that it was a mistake
for Associate Professor King to agree to the changes to the wording of the
recommendations without informing and obtaining the written consent of the rest
of the Supporting Committee. It was also a poor procedural decision not to
ensure that the changes made were clearly recorded as the Steering Committee's
when the draft Supporting Committee report was given to MSAC for its
consideration. However these deficiencies in the assessment process could also
reflect the quality of the secretariat support by the Department to both the Steering
Committee and the MSAC Supporting Committee.
1.100
The Committee has considered the matters raised by Dr Ware
in relation to the evidence provided by officers of the Department of Health
and Ageing. The Committee is concerned about the quality of the responses from
the Department to questions on notice during earlier estimates hearings. The
answer provided by the Department to Senator Harradine's question on notice
(E03-045) is wrong, disingenuous and unhelpful, at best, when considered next
to the wording of the report of the MSAC Supporting Committee on 23 March 2000. The Department has always tried to justify its response saying that it was
literally correct. It was not. The Department had in its possession documents
that demonstrated what the findings of the true Supporting Committee report
were that PET was clinically effective.
- It is not correct to state that Supporting Committee’s do not
make reports or findings, as demonstrated by the material included in this
report.
- There is no evidence that MSAC were informed that Supporting
Committee members held stronger views.
- The experts' opinions were ignored by MSAC, given there true
opinions and findings were altered, without MSAC being aware of that fact.
1.101
The Committee notes that the Government Guidelines for
Official Witnesses before Parliamentary Committees and Related Material state
that it is the duty of the public servants 'to assist ministers to fulfil their
accountability obligations by providing full and accurate information to the
Parliament about the factual and technical background to policies and their
administration'. These guidelines are aimed at encouraging the freest possible
flow of such information between the public service, the Parliament and the
public.[94]
The Committee is concerned that the Department has not maintained this
standard.
1.102
In addition, the Committee wishes to record its disapproval
of the conduct of officers of the Department of Health and Ageing when appearing
to answer questions on this matter. At the hearing on 14 June 2007, Department
officers had not adequately prepared to answer relevant questions from Senators
and frequently had to take questions on notice. Delayed responses to the
questions taken on notice have made it difficult for the Committee to finalise
its deliberations in this matter. Some answers particularly those in answer to Senator
Harradine and to the Committee (Ms Halton's letter of 19 February 2008) appear to have been designed to mislead contrary to the duty of public
servants as noted above. The Committee considers that it is likely this matter
would have been dealt with considerably earlier if the Department of Health and
Ageing had been more effective in communicating information, either in response
to Senators' questions, in response to freedom of information requests or
otherwise.
1.103
The Committee notes the Department now intends to offer Professor
Hicks an erratum to appear on the MSAC website. However, given the range of
views expressed by the other members of the Supporting Committee, the Committee
considers that they should also be offered the opportunity to have their
dissent acknowledged.
Recommendation 1
1.104
The MCSAC 2000
assessment of PET be withdrawn.
Recommendation 2
1.105
That Department of Health and Ageing and the Medical Services Advisory
Committee coordinate to issue a disclaimer or erratum to institutions likely to
hold physical or electronic copies of the MSAC Assessment Report: Positron Emission
Tomography or the Report of the Review of Positron
Emission Tomography to indicate which members of the
Supporting Committee did not agree that the final report reflected their views.
Recommendation 3
1.106
MSAC, like the Pharmaceutical Benefits Advisory Committee be constituted
as a statutory body at arm's length from government.
Recommendation 4
1.107
The Department be required to provide documentary evidence of who
inserted the "Primary Finding" of the 2000 PET Review.
Recommendation 5
1.108
The Australian Public Sector Commissioner be asked to inquire into,
report on and recommend action on the Department's conduct in relation to PET
with regard to the APS Code of Conduct and its responsibility to assist
Ministers "to fulfil their accountability obligations by providing full
and accurate information to the Parliament about the factual and technical
background to policies and their administration".
Senator Christine Milne
Australian Greens, Tasmania |
Senator Lyn Allison
Australian Democrats, Victoria |
Navigation: Previous Page | Contents | Next Page